EyePoint Pharmaceuticals Inc (EYPT)
12.06
+0.30
(+2.55%)
USD |
NASDAQ |
Nov 01, 16:00
12.07
+0.01
(+0.08%)
After-Hours: 20:00
EyePoint Pharmaceuticals Max Drawdown (5Y): 93.95% for Oct. 31, 2024
Max Drawdown (5Y) Chart
Historical Max Drawdown (5Y) Data
| Date | Value |
|---|---|
| October 31, 2024 | 93.95% |
| September 30, 2024 | 93.95% |
| August 31, 2024 | 93.95% |
| July 31, 2024 | 93.95% |
| June 30, 2024 | 93.95% |
| May 31, 2024 | 93.95% |
| April 30, 2024 | 93.95% |
| March 31, 2024 | 93.95% |
| February 29, 2024 | 93.95% |
| January 31, 2024 | 93.95% |
| December 31, 2023 | 93.95% |
| November 30, 2023 | 93.95% |
| October 31, 2023 | 93.95% |
| September 30, 2023 | 93.95% |
| August 31, 2023 | 93.95% |
| July 31, 2023 | 93.95% |
| June 30, 2023 | 93.95% |
| May 31, 2023 | 93.95% |
| April 30, 2023 | 93.95% |
| March 31, 2023 | 93.95% |
| February 28, 2023 | 93.71% |
| January 31, 2023 | 93.71% |
| December 31, 2022 | 93.71% |
| November 30, 2022 | 92.21% |
| October 31, 2022 | 92.21% |
| Date | Value |
|---|---|
| September 30, 2022 | 92.21% |
| August 31, 2022 | 92.21% |
| July 31, 2022 | 92.21% |
| June 30, 2022 | 92.21% |
| May 31, 2022 | 92.21% |
| April 30, 2022 | 92.21% |
| March 31, 2022 | 92.21% |
| February 28, 2022 | 92.21% |
| January 31, 2022 | 92.21% |
| December 31, 2021 | 92.21% |
| November 30, 2021 | 92.21% |
| October 31, 2021 | 92.21% |
| September 30, 2021 | 92.21% |
| August 31, 2021 | 92.21% |
| July 31, 2021 | 92.21% |
| June 30, 2021 | 92.21% |
| May 31, 2021 | 92.21% |
| April 30, 2021 | 92.21% |
| March 31, 2021 | 92.21% |
| February 28, 2021 | 92.21% |
| January 31, 2021 | 92.21% |
| December 31, 2020 | 92.21% |
| November 30, 2020 | 92.21% |
| October 31, 2020 | 92.21% |
| September 30, 2020 | 90.01% |
Max Drawdown Definition
Max drawdown is an indicator of the risk of a portfolio chosen based on a certain strategy. It measures the largest single drop from peak to bottom in the value of a portfolio before a new peak is achieved.
Max Drawdown (5Y) Range, Past 5 Years
80.86%
Minimum
Nov 2019
93.95%
Maximum
Mar 2023
91.33%
Average
92.21%
Median
Oct 2020
Max Drawdown (5Y) Benchmarks
| Cassava Sciences Inc | 92.93% |
| Adverum Biotechnologies Inc | 97.89% |
| Regenxbio Inc | 84.15% |
| Editas Medicine Inc | 96.80% |
| Apellis Pharmaceuticals Inc | 74.65% |
Max Drawdown (5Y) Related Metrics
| Alpha (5Y) | -33.96 |
| Beta (5Y) | 1.499 |
| Annualized Standard Deviation of Monthly Returns (5Y Lookback) | 155.8% |
| Historical Sharpe Ratio (5Y) | -0.0938 |
| Historical Sortino (5Y) | -0.3649 |
| Monthly Value at Risk (VaR) 5% (5Y Lookback) | 35.60% |